For her, finally, the job is done.
“Being able to modify the vaccine to adapt it to the variants was the initial contract, the big advantage of messenger RNA, recalls researcher Morgane Bomsel, immunologist at the Paris Cochin Institute.
You can almost wonder why it wasn't faster..." In any case, after several months of hard work, Pfizer-BioNTech and Moderna, the two companies using this revolutionary technology, have now developed their next-generation vaccines. .
Subscribe to read more
Already subscribed?
To log in
